A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 May 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ALPS
- Sponsors AstraZeneca
- 08 May 2017 Planned End Date changed from 1 Jun 2017 to 25 Jul 2017.
- 08 May 2017 Planned primary completion date changed from 1 Jun 2017 to 25 Jul 2017.
- 13 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.